01 — Market Intelligence Brief
Global Gelatin Capsule Market Sizing, segmenting and stress-testing the next five years of oral oral dosage delivery. 2024 Market Size
2030 Projection
$5.85B
$8.08B
Anchor year · Next Move intelligence base
Forecast · patient + supplement demand
Reference · Oral dosage
5.5%
Five-year CAGR, 2025 → 2030
$5.85B
$8.08B
How the market is segmented
By Type
By Raw Material
By Application
By Region
Hard Soft
Bovine Porcine · Other
Pharmaceutical Nutraceutical
Europe · N. America Asia-Pacific · RoW
Executive Summary
The market is in a steady compounding phase: pharma spend rises, formulation flexibility widens, and Asia-Pacific pulls demand — while plantplant-based innovation opens a parallel track.
15
Companies profiled across the value chain
28
Countries covered across four regions
© 2024 Next Move Strategy Consulting · All rights reserved.
Source · Next MSC Gelatin Capsule Market Report, 2024
Growth Drivers & Opportunities
Where demand compounds through 2030. Reference · Variants
Five structural forces are pulling the category forward — and four Demand Drivers regions are absorbing the demand at very different speeds.
$40B
+8.4%
China nutraceutical market, 2023
Pharma prescription spend uplift, U.S.
Formulation flexibility
International Trade Administration: +14% yearCMS data shows U.S. Rx spend climbed to USD
on-year, fueling supplement demand for
Capsules carry powders, granules, liquids and select
USD 405.9B in 2022, up from 6.8% growth in
capsule formats.
semi-solids — broadening therapeutic surface area.
growth in 2021. Powder
Granule
Innovation Pipeline
High-Growth Segment
Plant-based and TiO₂-free platforms
India pharmaceutical expansion
Lonza introduced TiO₂-free hard capsules in May 2022 using crystalline-
USD 130B
crystalline-salt opacifiers; IFF launched Verdigel SC pectin premix in April
Liquid
Semi-solid
60%
premix in April 2023.
Regional Opportunities
Where the next leg of growth is loaded. loaded. 01 · Dominant
02 · Rising
03 · Mature
04 · Emerging
Europe
Asia-Pacific Pacific
North America
Rest of the World
Holds the dominant share; plantplant-based alternatives accelerating (~150M Europeans Europeans with allergies).
Pharma + nutraceutical surge: China $40B nutraceuticals, India $130B pharma target by 2030.
Rx drug spend growing at +8.4% in 2022; established supplement consumer base.
PRIMARY MARKET
FASTEST LANE
© 2024 Next Move Strategy Consulting · All rights reserved.
STEADY CURRENT
LATAM, MENA, Africa — early-stage but unlocks; local manufacturing partnerships emerging.
WATCH
Source · CMS, ITA, WHO, Indian Pharmaceutical Association
Competitive Scenario
Strategic posture across 15 profiled companies. A mid-fragmented field where innovation, M&A and CDMO partnerships are setting the setting the leaders apart. Leading companies
Share disclosed · 10 of 15
Tier-1
ACG
Tier-1
Lonza
Tier-1
Qualicaps
Global CDMO; ComboCap acquisition acquisition in Mar 2023
TiO₂-free hard gelatin capsules (May 2022)
Hard and soft gelatin across pharma + pharma + nutraceutical
HBI Eurocaps
Nectar Lifesciences Lifesciences
Sunil Healthcare
Tier-2
(DCC plc Group) · diversified capacity capacity
Tier-2
Tier-2
Innovator
+7 more
Long tail
Caps Canada · EMBOCAPS · Erawat · Dah Dah Feng · Fortcaps · GoCaps · Empty Capsules
Empty capsules + healthcare formulations
India-based; pharma-focused gelatin gelatin
GELITA AG
Strategic positioning
Innovation intensity × Scale Where capital is moving Specialists
Leader Quadrant
GLT
LZA
ACG
I n n o v a ti o n ↑
QCP
01 · Innovation Plant-based, TiO₂-free, easy-seal technologies. Verdigel SC, ComboCap 2-in-1 caps.
02 · M&A & Alliances ACG Vantage Nutrition acquired ComboCap; CDMOs announcing announcing specialty soft-gel launches at CPHI Barcelona. Barcelona.
03 · Geographic expansion Niche
High-Volume
Scale →
© 2024 Next Move Strategy Consulting · All rights reserved.
Source · Next MSC company profiles + disclosed announcements
Strategic Outlook
Four capital implications for the next 36 months. The shape of the opportunity, the seams where incumbents are vulnerable, and where disciplined capital can compound.
Implication 01
01
Implication 02
02
Capacity closer to Asia-Pacific demand demand
Premiumize through plant-based TiO₂-free, vegan and pectin-based capsules command a premium wedge in Europe, where ~150M residents live with allergies. PRICING · MARGIN EXPANSION
Implication 03
CAPEX · REGIONAL FOOTPRINT
03
Watchlist · Risk
!
Consolidate the long tail
Allergen & substitution drag
15 companies profiled, 10 with disclosed share — mid-fragmented. ACG's
Animal-sourced gelatin triggers skin and respiratory reactions; plant-based
ComboCap deal signals roll-up potential in specialty formats.
cost differential persists; drug-device convergence remains a long-tail risk.
M&A · ROLL-UP THESIS
DILIGENCE PRIORITY
Forward Signal · 36-Month Horizon Map
What to track, when to lean in.
0–12
Capacity, TiO₂-free and CDMO partnerships
months
Watch for new plant-based premixes and tier-1 expansion in Asia.
12–24 24 months
24–36
Specialty formulations + M&A roll-up 2-in-1 caps, soft-gel for menopause / eye health, niche consolidation.
Active-ingredient shells + platform plays Embed actives directly into shell; move from commodity to drug-delivery platform.
Build Near-term capex + product
Acquire Selective, capability-led
Reinvent Platform optionality
months
© 2026 Next Move Strategy Consulting · All rights reserved.
Compiled by Next MSC Strategy · Investor intelligence brief
Thank You
Let's continue the conversation. Website
nextmsc.com
Get the full report
nextmsc.com/report/ gelatin-capsule-market
Phone
+1 857-758-5017 Open the report → Email
info@nextmsc.com
Follow Us
Li
Fb
YT
YouTube
X
Ig